Dec. 18 at 8:56 PM
$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger):
“….where AMGN’s avacopan could limited
therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week
basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with
successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while
the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of
clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate
a new MoA across this multibillion dollar indication market.
Initiation of a Phase II
program for Izicopan….
Also mentioned as hidden gems:
$RAPT $PHAT $SION $FBRX
